Over the last three decades, several tools have been developed to enhance the detection and treatment of neonatal seizures. Regarding treatment, phenobarbital maintains is still used as a first-line therapy worldwide. However, newer anti-epileptic drugs (AED) s such as, levetiracetam, bumetanide, and topiramate are increasingly being applied to the neonatal population, offering the potential for seizure treatment with a significantly better side-effect profile. Levetiracetam is a very promising medication for the treatment of neonatal seizures. It has been in clinical use for almost a decade in adults and older children with good efficacy, an excellent safety profile and near ideal pharmacokinetic characteristics. It has been approved and used for treatment of seizures in infants starting one month of age since 2012. The investigators are comparing the efficacy of levetiracetam to that of phenobarbital as a first-line drug in control of neonatal seizures. The investigators monitor the efficacy through assessment of frequency of seizures before and after drug administration, amplitude integrated EEG changes in background activity and seizure frequency in participants, duration taken for participants to be seizure free and short term neurodevelopmental outcome and EEG at 3 months of age
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
40
Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
Cairo University Children's Hospital (Abulreesh)
Cairo Governorate, Egypt
RECRUITINGEfficacy of levetiracetam in control of neonatal seizures as a first line versus phenobarbital through assessment of seizure burden.
Number of seizures before and after levetiracetam administration in comparison to phenobarbital.
Time frame: 72 hours
Efficacy of levetiracetam in rapid control of neonatal seizures compared to phenobarbital.
Number of hours taken to achieve seizure freedom after administration of levetiracetam versus phenobarbital.
Time frame: 72 hours
Dose escalation data about levetiracetam through studying the efficacy of further dose administration in non responders.
Number of originally non responder participants who achieved seizure control with higher doses of levetiracetam.
Time frame: 72 hours
Adequacy of levetiracetam as a single agent antiepileptic drug in control of neonatal seizures.
Number of participants who require addition of second line antiepileptic drug to control seizures after levetiracetam versus phenobarbital use.
Time frame: 30 days
Accuracy of amplitude integrated EEG monitoring in detecting neonatal seizures before and after antiepileptic drug use.
Number of seizures detected by aEEG before and after antiepileptic drug use.
Time frame: 48 hours
Effect of levetiracetam on aEEG background activity of participants.
Number of participants with normalization of background activity after administration of levetiracetam versus phenobarbital.
Time frame: 48 hours
The short term clinical outcome of patients with neonatal seizures after treatment with levetiracetam.
Neurodevelopmental assessment through detecting presence of following milestones: 1. Head control 2. Social smile 3. Visual fixation and pursuit 4. Turning towards sounds
Time frame: 3 months
The short term electroencephalographic outcome of patients with neonatal seizures after treatment with levetiracetam
Number of participants with presence of epileptogenic activity on follow up electroencephalogram.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.